Oral Anticoagulation

Continuing Anticoagulation After Unprovoked VTE Lowers Recurrence but Raises Bleeding — Real‑World Target Trial Emulation Shows Net Clinical Benefit

By MedXY 11/22/2025

A large target‑trial emulation of US claims data found continued oral anticoagulation after ≥90 days for unprovoked VTE markedly reduced recurrent VTE and mortality, increased major bleeding, but produced an overall net clinical benefit that persisted through several years of follow‑up.

Cardiology news

NOAC Monotherapy After Drug‑Eluting Stent: Safer and at Least as Effective as NOAC Plus Clopidogrel in AF Patients ≥1 Year After PCI

By MedXY 11/10/2025

In the ADAPT AF‑DES randomized trial, NOAC monotherapy in AF patients with drug‑eluting stents implanted ≥1 year earlier reduced bleeding and was noninferior—and numerically superior—for a composite of ischemic and bleeding outcomes versus NOAC plus clopidogrel at 12 months.

Cardiology news

Aspirin Use in Chronic Coronary Syndrome Patients on Oral Anticoagulation: Balancing Risks and Benefits

By MedXY 10/31/2025

A randomized trial revealed that adding aspirin to oral anticoagulation in chronic coronary syndrome patients increases adverse cardiovascular events, mortality, and major bleeding, challenging conventional dual therapy approaches.